Lung cancer drug combo study halted early

NCT ID NCT04924192

First seen Apr 20, 2026 · Last updated Apr 25, 2026 · Updated 3 times

Summary

This study tested a new drug combination (TQB3616 plus anlotinib or standard chemo) in 21 people with advanced lung cancer that had worsened after prior treatments. The goal was to see if the combo could shrink tumors or slow the disease. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400000, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, 550002, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, 730000, China

  • The Second Affiliated Hospital of PLA Air Force Military Medical University

    Xi’an, Shanxi, 710038, China

  • West China Hospital of Sichuan University

    Chengdou, Sichuan, 610041, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, 650011, China

Conditions

Explore the condition pages connected to this study.